ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Summary

A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).

Timeline

Start

2021-07-14

Primary completion

2022-12-30

Completion

2023-06-30

Publications

• Li T, Lin M, Wang B, Zhao M, Cao J, Wang L, Tao Z, Jin J, Miao H, Gong C, Zhao Y, Peng W, Hu X, Zhang J. Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China. EClinicalMedicine. 2025 Oct 30;90:103614. doi: 10.1016/j.eclinm.2025.103614. eCollection 2025 Dec.

Drugs

Indications